Stockreport

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

Aldeyra Therapeutics, Inc.  (ALDX) 
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aldeyra.com/investor-relations
PDF Clinical Results and Potential New Drug Application Submission Expected in the Second Half of 2024 LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasd [Read more]